Navigation Links
Avicena Reports Second Quarter 2007 Results
Date:8/31/2007

property portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company's pipeline includes drugs for Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS) and Huntington's disease. Avicena's Parkinson's disease candidate, PD-02, is currently in Phase III testing with the National Institutes of Health in one of the largest Parkinson's disease trials ever conducted. AL-02, the company's ALS candidate, and HD-02, its treatment for Huntington's disease, are soon expected to enter Phase III testing. Unlike traditional biotechnology companies, government and non-profit organizations largely fund Avicena's clinical programs. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

SAFE HARBOR

This release contains forward-looking statements that reflect, among other things, management's current expectations, plans and strategies, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See "Risk Factors" under "Item 6. Management's Discussion and Analysis of Financial Condition and Results of Operation" from our Annual Report on Form 10-KSB for the year ended December 31, 2006, and other descriptions in the company's public filings with the Securities and Exchange Commission for a discussion of such risks, including the company's need for additional funds, the company's dependence on a limited number of therapeutic compounds, the stage of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 EvoDerma ’s NOOME Anti-Aging ... rejuvenating device now comes with a second treatment cup to ... , The new cup is thinner on the edges for ... target rough, thin and uneven surfaces on the face, neck ... a stimulating treatment on areas such as the cheeks and ...
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
(Date:7/10/2014)... D.C., June 17, 2014 Using microscopic polymer ... specific gases, researchers at MIT,s Quantum Photonics Laboratory ... levels in the parts-per-billion range. Optical sensors are ... their high signal-to-noise ratio, compact, lightweight nature, and ... gas sensors had been developed before, the MIT ...
(Date:7/10/2014)... geckos and spiders can sit upside down forever. Nanophysics makes ... this in an article just published in Physical Review ... , Geckos and spiders that seem to be able to ... researchers worldwide for many years. We will soon be able ... as the gecko,s foot. But the fact is, sooner or ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Swell new sensors 2Even geckos can lose their grip 2
... Hayden, secretary of the Wisconsin Department of Health ... chief administrative officer for Dean Health Systems , ... use of health information technology, particularly Wisconsin's eHealth ... IT adoption. , ,His 23-year career in healthcare administration ...
... attack on multiple flanks. Google , the Internet utility and ... March 2007, according to Hitwise , is drawing out entrepreneurs ... can slay the giant. One intriguing possibility is evident in the ... talking about a merger or other sharing of capabilities, according to ...
... has announced that Berbee Information Networks , which is ... $250,000 in state Technology Zone tax credits. , ,Berbee, founded ... building and a 51,500-square-foot data center in the New Venture ... , ,The project is expected to cost $1.9 million and ...
Cached Biology Technology:DHC 2007: Hayden says technology creates magic moment for healthcare delivery 2DHC 2007: Hayden says technology creates magic moment for healthcare delivery 3DHC 2007: Hayden says technology creates magic moment for healthcare delivery 4Outflanking the Google, Yahoo, MSN juggernaut 2Outflanking the Google, Yahoo, MSN juggernaut 3Outflanking the Google, Yahoo, MSN juggernaut 4Outflanking the Google, Yahoo, MSN juggernaut 5Outflanking the Google, Yahoo, MSN juggernaut 6
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
(Date:7/10/2014)... , July 7, 2014 Fingerprint Cards, ... major design win (DW). A Chinese Top 5 smartphone OEM ... start of mass production in October 2014.   ... Top 5 smartphone OEM, which has a planned date for ... target sales volume for this phone of 3 million units. ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new ... (DW). An Asian OEM has selected FPC1021 for a flagship ... August 2014.   FPC is proud to announce ... planned date for start of mass production in August 2014. ... 5M, for delivery in the first half of July. The ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... from two universities in Italy and Virginia Tech in ... protein that is responsible for the production xanthurenic acid ... plays a key role in the sexual reproduction of ... Interfering with the formation of XA could be an ...
... Results from a new, five-year study show that regular use ... breast cancer by up to 71 percent and may offer ... cancers. , The study findings were released today at ... in Washington, D.C. , "We believe this is the ...
... you ever tried to do the limbo? For ants it's ... have discovered that ants are able to learn how to ... can successfully crawl under it without slowing down. Tobias Seidl ... Meeting for the Society for Experimental Biology on Tuesday 4th ...
Cached Biology News:Oxidation defense in mosquitoes benefits malaria parasite 2COX-2 inhibitors significantly reduce risk of cancer 2
... template is designed to allow kanamycin/neomycin ... It combines a prokaryotic promoter (gb2) ... E.coli with a eukaryotic promoter (PGK) ... cells. The prokaryotic promoter gb2 is ...
... The loxP-PGK-gb2-neo-loxP template is designed ... and eukaryotic cells. The loxP-PGK-gb2-neo-loxP ... which combines a prokaryotic promoter (gb2) ... E.coli with a eukaryotic promoter (PGK) ...
... This depletion cocktail is ... T cells from suspensions of ... separated using the StemSep (or ... cell selection system. The CD4+ ...
Standard Fluka For microscopy (Hist.) redox indicator...
Biology Products: